Clinical Trial

Ultrasound Evaluation of Hematoma Risk After Needle EMG in Patient on DOAC Therapy

Study acronym: U-HAND
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 10, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Approximately 30 minutes after needle EMG, patients who are taking direct oral anticoagulants (DOACs) will undergo an ultrasound examination to evaluate for the presence of possible intramuscular hematomas at the muscles where the EMG needle was inserted. These hematomas are considered a potential adverse effect of needle EMG. The aim of the study is to determine whether needle EMG can be considered a safe procedure in this group of patients, without posing a risk of intramuscular hematoma formation.
Trial Details
NCT Number NCT07166302
Lead Sponsor Masaryk University
Collaborators: Brno University Hospital
Conditions Direct Acting Anticoagulant Adverse Reaction, Needle Injury, EMG, Peripheral Neuropathies, Mononeuropathies, Polyneuropathies, Neuromuscular Diseases (NMD)
Enrollment 70 participants
Start Date 2025-09
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-10